PBC News
The Canadian PBC Society is committed to advocating for people living with PBC. In the spring of 2026, 324 people living with PBC from across
August 6, 2026
No Comments
Blog
Category: PBC News
- Home
- Category: PBC News
PBC News
Gilead Science Inc announced that Health Canada has approved LYVDELZI® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA)
October 23, 2025
No Comments
April 28, 2025 – Ipsen Biopharmaceuticals Canada Inc. today announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving IQIRVO® (elafibranor) for the
April 30, 2025
No Comments
FOR RELEASE ON JULY 5, 2024 7:00 AM EST – NEW YORK / TORONTO PBCers and Canadian PBC Society Press Release for PBC Patients: Important
July 5, 2024
No Comments
Clinical Trials
The 52-week IDEAL study aims to enroll 75 patients with PBC who have an incomplete response or intolerance to ursodeoxycholic acid (UDCA), in each case
August 14, 2023
No Comments
Clinical Trials
Ipsen and GENFIT announce positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational
June 30, 2023
No Comments
Clinical Trials
Intercept Pharmaceuticals announces new data showing potential of Fixed-Dose Combination of OCA and Bezafibrate to normalize multiple biomarkers in PBC to be featured in podium
June 11, 2023
No Comments
Clinical Trials
The GLISTEN clinical trial is investigating a potential new treatment specifically for PBC itch and is now enrolling patients worldwide. In Canada, the study is
May 31, 2023
No Comments
Clinical Trials
Intercept Pharmaceuticals is investigating a fixed-dose combination of OCA and bezafibrate for the potential treatment of individuals with PBC. Clinical trials are underway to establish
May 18, 2023
No Comments
Clinical Trials
The Phase 2 PACIFIC study will enroll approximately 58 patients with moderate-to-severe pruritus due to PBC or PSC. Now enrolling in Canada, see what’s involved
March 1, 2023
No Comments